Session 5: Treatment of HHT

09 Jun 2017
8:00 am – 9:45 am
Soderini Ballroom II, III

Session 5: Treatment of HHT

Invited Speaker:  Dr. Charles Theuer  (8:00am – 8:45am)

Treatment Manifestations of an Endoglin Antibody


Oral Presentations

8:45am – 9:00am

Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangiectasia: a randomized clinical trial

Dupuis-Girod S, Ambrun A, Decullier E, Fargeton AE, Roux A, Bréant V, Colombet B, Rivière S, Cartier C, Lacombe P, Chinet T, Blivet S, Blondel JH, Gilbert-Dussardier B, Dufour X, Michel J, Harle JR, Dessi P, Faure F


9:00am – 9:15am

Embolotherapy of pulmonary arteriovenous malformations with the MVP micro vascular plug: technical success and intermediate-term follow up

Ishaque B, Hetts S, Kerlan R, Dickey M, Wilson M, Conrad M


9:15am – 9:30am

Bevacizumab (Avastin) treatment for severe pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia

Mei-Zahav M, Rosengarten D, Issachar A, Blau H, Stemmer S, Kramer M


9:30am – 9:45am

Pazopanib reduces bleeding in hereditary hemorrhagic telangiectasia?

Faughnan ME, Gossage JR, Chakinala MM, Oh SP, Kasthuri R, Hughes CCW,

McWilliams J, Parambil JG, Donaldson J, Gitanjali Paul, Berry P, Sprecher D